Table 3 Clinical and demographic characteristics of patients with and without clinical cure
Clinical cure | Clinical failure | P-value | |
|---|---|---|---|
(n = 72) | (n = 19) | ||
Male sex | 49 (68) | 17 (89.5) | 0.06 |
Age, years* | 66.5 (24–88) | 67 (41–84) | 0.59 |
APACHE II* | 11 (2–28) | 13.5 (6–24) | 0.05 |
Co-morbidities, n (%): | |||
Malignancy | 11 (15.3) | 3 (15.8) | 1 |
Cardiovascular | 21 (29.2) | 5 (26.3) | 1 |
Pulmonary | 24 (33.3) | 9 (47,4) | 0,26 |
Diabetes Mellitus | 20 (27.8) | 1 (5.3) | 0.06 |
Urogenitala | 11 (15.3) | 3 (15.8) | 1 |
Hepatic | 8 (11.1) | 8 (0) | 0.2 |
Haematologicalb | 9 (12.5) | 3 (15.8) | 0.7 |
Neurologicalc | 16 (22.2) | 2 (10.5) | 0.34 |
Charlson* | 4.5 (0–10) | 4 (1–9) | 0.73 |
McCabe** | 1.4 ± 0.6 | 1.7 ± 0.7 | 0.11 |
Severe sepsis, n (%) | 49 (68.1) | 9 (47.4) | 0.095 |
Shock | 6 (8.3) | 1 (5.3) | 0.65 |
Patients with CKD at baseline | 16 (22.2) | 3 (15.8) | 0.53 |
Department of hospitalization: | |||
Medical | 38 (52.8) | 6 (31.6) | 0.16 |
Surgical | 23 (32) | 9 (47.4) | |
ICU2 | 11 (15.3) | 4 (21.1) | |
Admission diagnosis category: | |||
Infection | 19 (26.4) | 7 (36.8) | |
Other-medical | 30 (41.7) | 5 (26.3) | |
Other-surgical | 23 (3.9) | 7 (36.8) | 0.45 |
CMS daily dose (millions IU)** | 5.3 ± 2.3 | 6.2 ± 2.1 | 0.094 |
CMS total dose (millions IU)** | 105.91 ± 88.9 | 141.2 ± 129.5 | 0.45 |
CMS duration of treatment, days** | 20.66 ± 16.1 | 22.6 ± 18.5 | 0.81 |
Combined treatment, n (%) | 35 (48.6) | 11 (57.9) | 0.47 |
Css (mg/mL)** | 1.49 ± 1.4 | 2.42 ± 1.49 | 0.01 |
Css > 1.25 (mg/mL), n (%) | 32 (45.1) | 14 (73.7) | 0.027 |
Css/MIC** | 3.13 ± 2.9 | 4.61 ± 2.86 | 0.03 |
AKI at day 7, n (%) | 18 (25) | 12 (63.2) | 0.002 |
AKI at the EOT, n (%) | 33 (45.8) | 16 (84.2) | 0.003 |
Length of stay, days** | 69.16 ± 59.5 | 70.8 ± 39.1 | 0.19 |